Info@ThinkPinkRocks.com

Forest Laboratories’ Colobreathe dry powder inhaler receives EMA approval

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa.

View post:
Forest Laboratories’ Colobreathe dry powder inhaler receives EMA approval

Share
1 Comment
  1. I’m gone to say to my little brother, that he should also pay a visit this webpage on regular basis
    to get updated from most recent gossip.

Leave a Reply

Solve : *
14 + 19 =